InNexus Biotechnology, Inc. Share Price

Equities

IXSBF

CA45771Q1046

Biotechnology & Medical Research

Market Closed - OTC Markets 01:10:21 30/01/2024 am IST 5-day change 1st Jan Change
0.000001 USD -.--% Intraday chart for InNexus Biotechnology, Inc. -.--% -.--%
Sales 2009 - Sales 2010 - Capitalization 2.89M 241M
Net income 2009 -8M -668M Net income 2010 -6M -501M EV / Sales 2009 -
Net Debt 2009 3.35M 280M Net Debt 2010 5.64M 471M EV / Sales 2010 -
P/E ratio 2009
-0.92 x
P/E ratio 2010
-0.36 x
Employees 10
Yield 2009 *
-
Yield 2010
-
Free-Float 92.4%
More Fundamentals * Assessed data
Dynamic Chart
1 year
0.00
Extreme 0
0.00
3 years
0.00
Extreme 0
0.00
5 years
0.00
Extreme 0
0.00
10 years
0.00
Extreme 0
0.00
More quotes
Innexus Biotechnology Inc is a Canada-based development-stage company. The Company is a drug development company focused on commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL) technology. It is engaged in monetizing its technology for its own product development projects whether independently, through collaborations with strategic partners and/or through business development activities for the licensing and sale of its technologies and services. The Company focuses on developing and marketing DXL technology to the biotechnology and pharmaceutical community by launching and developing multiple product candidates. These candidates include potential therapeutic and diagnostic products.
More about the company